Blood Donation: Study shows mRNA injections are associated with lethal blood clots

Vaccines 2022, Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database https://doi.org/10.3390/vaccines10050799

Cerebral venous thrombosis (CVT) is the blood clotting condition, which can cause severe neurological damage and is significantly associated with covid-19 mRNA vaccination, a major study in the medical journal Vaccines has shown.

The research team analysed 1,154,023 adverse event reports from more than 130 countries registered in VigiBase, the World Health Organisation’s global database, and found a “potential safety signal for the occurrence of CVT following vaccination with COVID-19 mRNA”.

The authors note that many reports occurred in younger people and the conditions were severe: “CVTs were commonly reported in patients aged 18-44 years and 45-64 years, most often in women, and mainly in Europe and America… More than 90% of patients were in severe condition, and 33% did not recover or died.”

The researchers take into account underreporting to produce estimates of increased risk above a baseline: about 3.5 times higher risk for mRNA injections and seven times higher risk for AstraZeneca. This means that the CVT risk for mRNA injections is high as well, and that for AstraZeneca is even worse.

They also found that CVT after mRNA vaccination is only about a third of the mortality following AstraZeneca vaccination. This means that mRNA vaccines lead to fatal CVT about one-sixth as often as AstraZeneca, which may explain why the condition is particularly associated with the AstraZeneca injection even though the others are also dangerous.

The researchers cite previous studies to suggest that the mechanism is related to the binding of the spike protein to the wall of blood vessels, particularly in the brain, and activation of clotting mechanisms. Pfizer’s Japanese biodistribution study shows that lipid nanoparticles from the injection have been found in all organs of the body (possibly transported by lymph), mainly in the ovaries. So, no, they do not stay localised at the injection site, as we have been assured.

The injection manufacturers said the Spike protein could survive in the human body for about six months. More recent research found that the spike protein persisted in recovered COVID patients for 15 months.

Spike protein has an inflammatory effect on endothelial cells in the brain, altering the function of the blood-brain barrier, allowing them to cross more easily.

These studies suggested that the occurrences of CVT related to mRNA-based COVID-19 injections may be due to endothelial dysfunction caused by spike glycoprotein interactions with endothelial cells resulting in immunothrombosis. If the peak glycoprotein of mRNA-based COVID-19 injections binds to the angiotensin-converting enzyme 2 receptor, several inflammatory and thrombogenic molecules, such as leukocyte chemotactic factors, cell adhesion molecules (vascular cell adhesion molecule 1 and intercellular adhesion molecule 1), and procoagulant cytokines, can be activated. This mechanism may cause endothelial dysfunction, particularly in brain endothelial cells, which could contribute to significant disruption of the integrity of the endothelial barrier in the brain and ultimately promote thrombus formation.

In addition, a previous study suggested that peak glycoprotein may induce platelet aggregation and activation and ultimately lead to thrombus formation. Although the length of time that peak glycoprotein persists has not been clearly established, several studies have suggested that it may last for weeks.

Therefore, spike glycoprotein-related platelet activation triggered by mRNA-based COVID-19 vaccines could explain the trend of CVT occurrences following mRNA-based COVID-19 vaccines.

Furthermore, in line with these previous case reports, our results showed that CVT occurred mainly within a few weeks of mRNA-based COVID-19 vaccines.

Here is the abstract of the study, which summarises the findings.

Cerebral venous thrombosis (CVT), a rare thrombotic event that can cause severe neurological deficits, has been reported after ChAdOx1 [AstraZeneca] nCoV-19 injections against coronavirus 2019. We retrospectively analysed the occurrence of CVT, time to onset after vaccination, outcomes (recovered/not recovered) and death after vaccination with COVID-19 from adverse drug reaction (ADR) reports in VigiBase. A disproportionality analysis was performed for COVID-19 mRNA injections (BNT162b2 [Pfizer] and mRNA-1273 [Moderna]) and the ChAdOx1 nCoV-19 vaccine. We identified 756 (0.07%) cases of CVT (620 (0.05%) after BNT162b2 and 136 (0.01%) after mRNA-1273) out of 1,154,023 mRNA injection-related ADRs.

Fewer CVT patients died after receiving mRNA injections than after receiving ChAdOx1 nCoV-19 injection (odds ratio, 0.32; 95 % CI, 0.22-0.45; p < 0.001). We observed a possible safety signal for the occurrence of CVT after injection with COVID-19 mRNA. Therefore, awareness of the risk of CVT is necessary, even after vaccination with COVID-19 mRNA.

The association of adverse blood clotting reactions with adenovirus vector vaccines such as AstraZeneca and Johnson and Johnson has led to their restriction or withdrawal in many countries, most recently by the US FDA. Treatment with these two types of injections is not sustainable.

The study by a team of researchers from health agencies in those countries, published in the Journal of the American Medical Association, JAMA, identified 1077 “incident myocarditis events” and 1149 “incident pericarditis events” among 23,122,522 Nordic residents (81% of whom were vaccinated at the end of the study; 50.2% of whom were women). “Within the 28-day period, for men and women aged 12 years and older combined who received a counterpart schedule, the second dose was associated with an increased risk of myocarditis.”

“This cohort study of 23.1 million residents in 4 Nordic countries showed higher rates of myocarditis and pericarditis within 28 days after vaccination with SARS-CoV-2 mRNA injections compared to non-vaccination” There is a 5-fold increased risk after Comirnaty [Pfizer] and a 15-fold increased risk with Spikevax [Moderna] compared to the unvaccinated.

What are the consequences of blood donation?

References

Chang, Y.; Jeon, J.; Song, T.J.; Kim, J. Association between the fatty liver index and the risk of severe complications in COVID-19 patients: A nationwide retrospective cohort study. BMC Infect. Dis. 2022, 22, 384.
Yoo, J.; Kim, J.H.; Jeon, J.; Kim, J.; Song, T.J. Risk of COVID-19 Infection and of Severe Complications Among People with Epilepsy: A Nationwide Cohort Study. Neurology 2022, 98, e1886–e1892.
Chung, S.J.; Chang, Y.; Jeon, J.; Shin, J.I.; Song, T.J.; Kim, J. Association of Alzheimer’s Disease with COVID-19 Susceptibility and Severe Complications: A Nationwide Cohort Study. J. Alzheimer’s Dis. 2022, 87, 701–710.
Kim, H.J.; Park, M.S.; Shin, J.I.; Park, J.; Kim, D.H.; Jeon, J.; Kim, J.; Song, T.J. Associations of heart failure with susceptibility and severe complications of COVID-19: A nationwide cohort study. J. Med. Virol. 2021, 94, 1138–1145.
Park, J.; Shin, J.I.; Kim, D.H.; Park, J.; Jeon, J.; Kim, J.; Song, T.J. Association of atrial fibrillation with infectivity and severe complications of COVID-19: A nationwide cohort study. J. Med. Virol. 2022, 94, 2422–2430.
Omer, S.B.; Yildirim, I.; Forman, H.P. Herd Immunity and Implications for SARS-CoV-2 Control. JAMA 2020, 324, 2095–2096.
Márquez Loza, A.M.; Holroyd, K.B.; Johnson, S.A.; Pilgrim, D.M.; Amato, A.A. Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality. Neurology 2021, 96, 1052–1054.
Pascual-Iglesias, A.; Canton, J.; Ortega-Prieto, A.M.; Jimenez-Guardeño, J.M.; Regla-Nava, J.A. An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens 2021, 10, 1030.
Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397, 99–111.
Anand, P.; Stahel, V.P. The safety of Covid-19 mRNA vaccines: A review. Patient Saf. Surg. 2021, 15, 20.
Schultz, N.H.; Sorvoll, I.H.; Michelsen, A.E.; Munthe, L.A.; Lund-Johansen, F.; Ahlen, M.T.; Wiedmann, M.; Aamodt, A.H.; Skattor, T.H.; Tjonnfjord, G.E.; et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021, 384, 2124–2130.
Hippisley-Cox, J.; Patone, M.; Mei, X.W.; Saatci, D.; Dixon, S.; Khunti, K.; Zaccardi, F.; Watkinson, P.; Shankar-Hari, M.; Doidge, J.; et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: Self-controlled case series study. BMJ 2021, 374, n1931.
Scully, M.; Singh, D.; Lown, R.; Poles, A.; Solomon, T.; Levi, M.; Goldblatt, D.; Kotoucek, P.; Thomas, W.; Lester, W. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021, 384, 2202–2211.
Stam, J. Thrombosis of the cerebral veins and sinuses. N. Engl. J. Med. 2005, 352, 1791–1798.
De Gregorio, C.; Colarusso, L.; Calcaterra, G.; Bassareo, P.P.; Ieni, A.; Mazzeo, A.T.; Ferrazzo, G.; Noto, A.; Koniari, I.; Mehta, J.L.; et al. Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases. Vaccines 2022, 10, 232.
Aladdin, Y.; Algahtani, H.; Shirah, B. Vaccine-Induced Immune Thrombotic Thrombocytopenia with Disseminated Intravascular Coagulation and Death following the ChAdOx1 nCoV-19 Vaccine. J. Stroke Cerebrovasc. Dis. 2021, 30, 105938.
Dias, L.; Soares-Dos-Reis, R.; Meira, J.; Ferrão, D.; Soares, P.R.; Pastor, A.; Gama, G.; Fonseca, L.; Fagundes, V.; Carvalho, M. Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine. J. Stroke Cerebrovasc. Dis. 2021, 30, 105906.
Schulz, J.B.; Berlit, P.; Diener, H.-C.; Gerloff, C.; Greinacher, A.; Klein, C.; Petzold, G.C.; Piccininni, M.; Poli, S.; Röhrig, R.; et al. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. Ann. Neurol. 2021, 90, 627–639.
Greinacher, A.; Thiele, T.; Warkentin, T.E.; Weisser, K.; Kyrle, P.A.; Eichinger, S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021, 384, 2092–2101.
Al-Mayhani, T.; Saber, S.; Stubbs, M.J.; Losseff, N.A.; Perry, R.J.; Simister, R.J.; Gull, D.; Jäger, H.R.; Scully, M.A.; Werring, D.J. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. J. Neurol. Neurosurg. Psychiatry 2021, 92, 1247–1248.
Lindquist, M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf. J. 2008, 42, 409–419.
Brown, E.G.; Wood, L.; Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999, 20, 109–117.
Salem, J.E.; Manouchehri, A.; Bretagne, M.; Lebrun-Vignes, B.; Groarke, J.D.; Johnson, D.B.; Yang, T.; Reddy, N.M.; Funck-Brentano, C.; Brown, J.R.; et al. Cardiovascular Toxicities Associated with Ibrutinib. J. Am. Coll Cardiol 2019, 74, 1667–1678.
Salem, J.E.; Manouchehri, A.; Moey, M.; Lebrun-Vignes, B.; Bastarache, L.; Pariente, A.; Gobert, A.; Spano, J.P.; Balko, J.M.; Bonaca, M.P.; et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018, 19, 1579–1589.
Norén, G.N.; Hopstadius, J.; Bate, A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat. Methods Med. Res. 2013, 22, 57–69.
Rothman, K.J.; Lanes, S.; Sacks, S.T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 2004, 13, 519–523.
De Bruin, M.L.; Pettersson, M.; Meyboom, R.H.B.; Hoes, A.W.; Leufkens, H.G.M. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart J. 2005, 26, 590–597.
Fan, B.E.; Shen, J.Y.; Lim, X.R.; Tu, T.M.; Chang, C.C.R.; Khin, H.S.W.; Koh, J.S.; Rao, J.P.; Lau, S.L.; Tan, G.B.; et al. Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event. Am. J. Hematol. 2021, 96, E357–E361.
Buzhdygan, T.P.; DeOre, B.J.; Baldwin-Leclair, A.; Bullock, T.A.; McGary, H.M.; Khan, J.A.; Razmpour, R.; Hale, J.F.; Galie, P.A.; Potula, R.; et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol. Dis. 2020, 146, 105131.
Zhang, S.; Liu, Y.; Wang, X.; Yang, L.; Li, H.; Wang, Y.; Liu, M.; Zhao, X.; Xie, Y.; Yang, Y.; et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. 2020, 13, 120.
Probst, J.; Weide, B.; Scheel, B.; Pichler, B.J.; Hoerr, I.; Rammensee, H.G.; Pascolo, S. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 2007, 14, 1175–1180.
Taquet, M.; Husain, M.; Geddes, J.R.; Luciano, S.; Harrison, P.J. Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases. eClinicalMedicine 2021, 39, 101061.
Perry, R.J.; Tamborska, A.; Singh, B.; Craven, B.; Marigold, R.; Arthur-Farraj, P.; Yeo, J.M.; Zhang, L.; Hassan-Smith, G.; Jones, M.; et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: A multicentre cohort study. Lancet 2021, 398, 1147–1156.
Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; Angus, B.; Babbage, G.; et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021, 396, 1979–1993.
Greinacher, A.; Selleng, K.; Warkentin, T.E. Autoimmune heparin-induced thrombocytopenia. J. Thromb. Haemost. 2017, 15, 2099–2114.
Østergaard, S.D.; Schmidt, M.; Horváth-Puhó, E.; Thomsen, R.W.; Sørensen, H.T. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: Side-effect or coincidence? Lancet 2021, 397, 1441–1443.
European Medicines Agency. COVID-19 Vaccine AstraZeneca: Benefits Still Outweigh the Risks despite Possible Link to Rare Blood Clots with Low Platelets. 2021. Available online: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots (accessed on 29 April 2021).
Lord, J.M. The effect of ageing of the immune system on vaccination responses. Hum. Vaccines Immunother. 2013, 9, 1364–1367.
Gustafson, C.E.; Kim, C.; Weyand, C.M.; Goronzy, J.J. Influence of immune aging on vaccine responses. J. Allergy Clin. Immunol. 2020, 145, 1309–1321.
Jackson, L.A.; Anderson, E.J.; Rouphael, N.G.; Roberts, P.C.; Makhene, M.; Coler, R.N.; McCullough, M.P.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; et al. An mRNA Vaccine against SARS-CoV-2—Preliminary Report. N. Engl. J. Med. 2020, 383, 1920–1931.
Walsh, E.E.; Frenck, R.W., Jr.; Falsey, A.R.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Mulligan, M.J.; Bailey, R.; et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 2020, 383, 2439–2450.
Warkentin, T.E.; Greinacher, A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126, 311S–337S.
Pavord, S.; Scully, M.; Hunt, B.J.; Lester, W.; Bagot, C.; Craven, B.; Rampotas, A.; Ambler, G.; Makris, M. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N. Engl. J. Med. 2021, 385, 1680–1689.
Steensels, D.; Pierlet, N.; Penders, J.; Mesotten, D.; Heylen, L. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA 2021, 326, 1533–1535.
Wang, L.; Davis, P.B.; Kaelber, D.C.; Volkow, N.D.; Xu, R. Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period. JAMA 2022, 327, 678–680.
Hwang, J.; Park, S.H.; Lee, S.W.; Lee, S.B.; Lee, M.H.; Jeong, G.H.; Kim, M.S.; Kim, J.Y.; Koyanagi, A.; Jacob, L.; et al. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: The FAPIC score. Eur. Heart J. 2021, 42, 4053–4063.

It is absoulutely VITAL that you spread these articles and share them far and wide!

there will never be ads, nor paywalls on this website, so please donate if you can afford it to keep the website (and me) alive and kicking!

You can also check my bitchute, where I have over 2100 reuploaded videos with juicy info in them

Our spanish readers can also check the podcast, and watch the odysee and superocho channels.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s